The healthcare sector, like many others, faces a challenging environment due to ongoing liquidity constraints. Venture capitalists and dealmakers are navigating through a period marked by tightened exit strategies, heightened valuations, and an overall unique set of dynamics. A recent Deloitte
Gene therapy has emerged as a revolutionary tool in modern medicine, offering new hope for individuals with genetic disorders. One such breakthrough is its application in treating hemophilia B, a rare and often debilitating blood disorder. But can gene therapy truly revolutionize the treatment for
AI startups targeting the healthcare sector have shown great promise in recent years, but they must navigate unique challenges to succeed. While the potential for innovation in clinical care, administrative efficiencies, and patient outcomes is immense, these startups must overcome several key
The European Union's pioneering AI Act, poised to dramatically alter the landscape of healthcare and life sciences across Europe, shines a spotlight on the urgent need for compliance among companies involved in AI applications from production to clinical operations. As the regulation drives
Gene therapy has ushered in a new era of medical possibilities, offering groundbreaking treatments for debilitating and often fatal diseases. One of the most prominent examples is Lenmeldy (atidarsagene autotemcel), a gene therapy developed by Orchard Therapeutics and recently acquired by Kyowa
Pharmaceutical safety is a multifaceted and crucial aspect of public health, involving systematic efforts, regulations, and the collective responsibility of individuals. Ensuring the efficacy and safety of drugs requires vigilance from regulatory bodies, healthcare professionals, the pharmaceutical
